Profile picture

Professor Stephen Bain

Swansea University, Swansea (United Kingdom of Great Britain & Northern Ireland)
Follow
Logo ESC

Contributor content

Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme
Presentation
Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme
Read more
Reduction in systolic blood pressure with semaglutide treatment is not due to weight loss alone: data from SUSTAIN 1-5
Presentation
Reduction in systolic blood pressure with semaglutide treatment is not due to weight loss alone: data from SUSTAIN 1-5
Read more
Connect with the speakers: questions & answers.
Presentation
Connect with the speakers: questions & answers.
Read more
Linking the dots: cardiovascular disease, type 2 diabetes and other comorbidities.
Presentation
Linking the dots: cardiovascular disease, type 2 diabetes and other comorbidities.
Read more

ESC 365 is supported by

novartis Explore sponsored resources